"Prostaglandin Study" from Glaucoma Associates of Texas

PRIMARY INVESTIGATOR: Dr. Godfrey

PURPOSE OF STUDY:

The purpose of this study is to compare the IOP (intraocular pressure) reducing effect of Latanoprost (Xalatan) versus Travoprost (Travatan) versus Bimatoprost (Lumigan) over a twelve-week period. All three drugs are FDA approved.

The second purpose is to study the safety variables within and between all treatment groups over 12 weeks.

50 enrolled patients will be randomly assigned to one of three treatments: Xalatan, Travatan or Lumigan. One drop will be administered to each affected eye every evening at (8:00 pm). Every 4 weeks a new study bottle will be administered.

Neither you nor the study doctor will know which medication you are given, however, in the event of an emergency, that information can be obtained.

DURATION OF SUBJECT PARTICIPATION:

There will be 5 visits over a 12 week period. Medical/ocular history will be obtained and a visual field may be needed, if one has not been done in 4 weeks. An examination of each eye will be preformed, along with visual acuity and IOP readings.

INCLUSION CRITERIA:

To be considered for enrollment into the study you must:

EXCLUSION CRITERIA:

You will not be able to participate in the study if you are a woman who is pregnant, nursing, or planning a pregnancy or if you are a woman of childbearing potential, not using a reliable means of contraception.

You will not be able to participate in the study if ANY of the following apply:

COMPENSATION:

The study exams and medication will be of no charge to you or your insurance company. Enrolled patients completing this study will be compensated for their time.

If you are interested in learning more about one of our Glaucoma Studies, please call Michelle Cochran at 214-360-0000 ext. 126 or email her at mcochran@medsynergies.com.

Glaucoma Associates of Texas
7150 Greenville Avenue, Suite 300
Dallas, TX 75231
Office: 214-360-0000
Fax: 214-360-0083

STUDY: Prostaglandin Study